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Leishmaniose e doença de Chagas, causadas pelos parasitas kinetoplastideos Leishmania 
spp e Trypanosoma cruzi, respectivamente, estão entre as doenças parasitárias mais importantes, 
afetando milhões de pessoas e consideradas dentro do grupo mais relevante de doenças tropicais 
negligenciadas. A principal alternativa para controlar essas parasitoses é a quimioterapia. No 
entanto, os atuais tratamentos quimioterápicos estão longe de serem satisfatórios. Esta revisão 
delineia o entendimento atual de diferentes fármacos contra leishmaniose e doença de Chagas e 
seus mecanismos de ação. As abordagens recentes na área de terapias anti-Leishmania e tripanocida 
também são enumerados, assim como a busca por novas drogas. 
Leishmaniasis and Chagas disease, caused by the kinetoplastid parasites Leishmania spp and 
Trypanosoma cruzi, respectively, are among the most important parasitic diseases, affecting millions 
of people and considered to be within the most relevant group of neglected tropical diseases. 
Chemotherapy is the main alternative to control such parasites, nevertheless, current treatments 
are far from satisfactory. This review outlines the current understanding on different drugs against 
leishmaniasis and Chagas disease and their mechanism of action. Recent approaches in the area of 
anti-leishmanial and trypanocidal therapies are also enumerated, as well as the search for new drugs.
Keywords: Visceral leishmaniasis, American tegumentary leishmaniasis, Chagas disease, 
Leishmania, Trypanosoma cruzi, chemotherapy
1. Leishmaniasis
Visceral leishmaniasis (VL), or kala-azar, is considered 
one of the oldest diseases of humanity, according to the 
World Health Organization (WHO).1 It has long been 
confused with other diseases, such as malaria. It was 
described for the first time only in 1822 and in 1903 its 
etiologic agent was identified.2 Charles Donovan found the 
parasite in the spleen of a Hindu child with irregular fever, 
but confused it for another protozoan, Trypanosoma brucei. 
After some false descriptions, Ronald Ross created the 
genus Leishmania and named the causative agent of visceral 
leishmaniasis, Leishmania donovani, in honor of William 
Boog Leishman and Charles Donovan.3 
The possible role of dogs in the epidemiology of 
leishmaniasis was suggested by Nicolle and Comte in 
1908, in Tunisia, after the detection of VL in animals.4 
The first human case described in Brazil was a patient 
originally infected in the Brazilian state of Mato Grosso 
and that migrated to Assunción in Paraguay.5 Penna6 in 1934 
described the parasite in liver of patients with yellow fever 
coming from the north and northeast of Brazil and one of the 
first observations of canine Leishmania infection was made 
by Chagas et al.,7 when he demonstrated the existence of the 
disease in man, dogs and Lutzomia longipalpis, classifying 
the parasite as Leishmania chagasi. 
Leishmaniasis is found in the tropical and subtropical 
regions and areas close to the Mediterranean. It is estimated 
that 350 million people are considered at risk of becoming 
infected with leishmaniasis and approximately 2 million 
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new cases are notified every year.1 The transmission of 
Leishmania spp is through the bite of female sand flies 
from the Phlebotomus genus in the Old World (Europe, 
Asia, Africa) and Lutzomyia genus in the New World 
(Americas).1 VL is mainly the result of infection by 
Leishmania donovani and Leishmania infantum (known 
as Leishmania chagasi in South America); sometimes, 
in few cases, Leishmania tropica in the Middle East and 
Leishmania amazonensis in South America can result 
in VL.8 Currently, VL is estimated to cause 12 million 
cases worldwide, with 200,000 to 400,000 new cases 
notified each year.9 Epidemiological studies have shown 
that more than 90% of VL are concentrated in only six 
countries: Bangladesh, Brazil, India, Sudan, South Sudan 
and Ethiopia, however, the prevalence of the disease is 
increasing in the Mediterranean region, Spain and France. 
Thus, VL is endemic in nine countries of the European 
Union (EU).10-13 Also, VL cases are reported in all 
continents, with exception of Antarctica.1,9
VL is a fatal form of leishmaniasis, due to the 
involvement of several organs, such as liver, spleen and 
bone marrow,14,15 with mortality rates ranging from 70 to 
95%, before the present chemotherapy was made available. 
Such mortality rates are among the highest reported for 
infectious diseases and show the severity of the parasite 
infection.
VL pathogenesis is initiated by the invasion of 
the mononuclear phagocyte system of some organs 
by Leishmania. In several cases it is accompanied by 
significant pathological alterations. Clinical manifestations 
are splenomegaly, hepatomegaly, as well as bone marrow 
involvement, and they result from the hypertrophy and 
hyperplasia of the macrophage system. Some organs with 
a high content of macrophage cells, such as the spleen, 
can affect lymphoid follicles and the circulation in the 
capillaries, causing severe congestion resulting in areas of 
ischemia. In the liver, considerable hypertrophy of Kupffer 
cells, crowding around the sinusoids or portal space, 
significantly affects this organ. Anemia is the result of the 
gradual replacement of the hematopoietic tissue by infected 
bone marrow macrophages.16,17 The clinical symptoms 
of VL infection are fever, weight loss, splenomegaly, 
hepatomegaly, anemia, leukopenia and thrombocytopenia. 
Such symptoms can be easily mistaken for other diseases if 
the clinician is not aware of the possibility of a Leishmania 
infection.18
Immunosuppression is a potential outcome of 
VL infection resulting in a reduction of the patient 
responsiveness and resistance to antigens from other 
infections. In chronic cases fibrosis of the spleen tissue is 
observed, which gradually leads to a complete change in 
the organ architecture accompanied by portal hypertension 
and ascites, among other events that lead to a gradual, and 
often fatal, organ failure. Co-infection of VL and human 
immunodeficiency virus (HIV) is considered of great 
importance to public health due to its mortality rates and 
geographical incidence.19,20 
Dermal leishmaniasis post-kala-azar is a potential 
secondary manifestation of L. donovani infection, 
especially in individuals who did not receive leishmaniasis 
treatment, resulting in skin lesions in the form of small 
nodules, erythematous macules, containing Leishmania 
cells in large amounts.21 
Besides the described VL, usually fatal if untreated, 
several different clinical forms of leishmaniasis are 
described. The most common forms are cutaneous 
leishmaniasis, which cause skin sores leading to disfiguring 
lesions.22,23 In South America, cutaneous leishmaniasis 
(CL), diffuse cutaneous leishmaniasis (DCL) and 
mucocutaneous leishmaniasis (MCL) are together termed 
the American tegumentary leishmaniasis (ATL).24 
ATL can be characterized by chronic skin ulcers. When 
they develop strictly to the site of the bite of the insect vector 
they are characterized as CL and can take several months 
to heal. MCL may be present as skin lesions similar to 
those of CL that heal spontaneously and reappear mainly 
in the mucosa of the nose and mouth. MCL is usually 
accompanied by secondary infections and destruction of the 
tissue. DCL, a rare form of leishmaniasis, causes infiltrative 
and non-ulcerating lesions in anergic individuals who do 
not respond to parasite antigens.24-27 
The pathogenesis of ATL is associated with host 
immune responses mediated by T cell and virulence 
of the infecting Leishmania species. The interaction 
between the different species of Leishmania and the 
immune response mechanisms result in a wide spectrum 
of clinical, histopathological and immunopathological 
manifestations in humans.28 In Brazil, ATL is caused by 
species of both Leishmania subgenera (L. amazonensis) 
and Viannia subgenera (L. braziliensis, L. guyanensis) 
and, exceptionally, L. shawi, L. naiffi, L. lainsoni and 
L. lindenbergi,29,30 posing an additional difficulty in ATL 
treatment due to the different drug response of each species 
to chemotherapy.
1.1. Current VL and ATL chemotherapy
Despite the long history of the discovery of human 
infection with Leishmania (VL and ATL), the main form of 
treatment for these diseases is still chemotherapy (Table 1). 
There is no effective vaccine available. Especially in the 
case of CL, the treatment is important to accelerate cure, 
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to reduce scars and to prevent parasite dissemination 
to mucosal sites, or relapse.51 Some characteristics of 
Leishmania parasites may affect treatment efficacy, such 
as different drug sensitivities of the several species that 
infect humans and the influence of immune suppression 
associated with leishmaniasis.52-55
Available antileishmanial drugs still depend on high doses 
of pentavalent antimonials, such as glucantime, meglumine 
antimoniate, pentostam and sodium stibogluconate 
(Figure 1) that result in severe side effects and require 
long-time treatment.56-58 After administration, pentavelent 
antimonials are rapidly absorbed and are converted into 
trivalent antimonite inside the macrophage, which is the 
active form of the drug.31,32 The reduction of pentavalent to 
trivalent antimony takes place either in the macrophages or 
in the parasite.33 A specific parasite enzyme involved in this 
reduction process was identified as thiol-dependent reductase 
(TDR1) and is capable of catalyzing the conversion of the 
pentavalent form of antimony to the trivalent one using 
glutathione as the reducing agent.34-36 Myalgia, nausea, 
liver and cardiac disorders, abdominal pain, headache, and 
asthenia are side effects often associated with such drugs.37 
Antimonials are also contraindicated in pregnancy and for 
patients with kidney, liver and heart diseases,38 reducing the 
effective use of the drugs.
A disadvantage of antimony is its rapid excretion by 
the kidneys, which makes a long-term administration of 
the drug necessary to achieve satisfactory therapeutic 
levels.39 The efficacy of treatment currently available is 
also compromised when there is immunosuppression, 
in particular due to co-infection with HIV, leading 
to exacerbation of the disease or emergence of latent 
infection.59 The antimonials have reduced activity in the 
absence of immune response mediated by T cells.60
Meglumine antimoniate (Figure 1) mechanism of action 
remains poorly known.40,41 It is believed that the mechanism 
Table 1. Summary of antileishmanial drugs
Drugs Mechanism of action Outcome Disadvantage Reference
Pentavalent antimony 
(Parenterally, daily, for at 
least three weeks 
(20 mg kg-1 day-1 for 
20-30 days)
Rapid absorption and inside the 
macrophage are converted into 
trivalent antimonite, which is 
the active form of the drug
TDR1a is capable of catalyzing 
the conversion of the 
pentavalent form of antimony to 
trivalent one using glutathione 
as the reducing agent
Side effects: myalgia, liver and 
cardiac disorders, abdominal 
pain, headache, asthenia. Its 
rapid excretion by the kidneys, 
which makes long-term 
administration of the drug 
necessary
31-39
Meglumine antimoniate 
(Glucantime®) 
(15 mg kg-1 day-1 for 
20 days)
Interference on amastigote 
bioenergetic process. Inhibits 
parasite proteins, as enzymes 
involved in glycolysis and fatty 
acid oxidation, reduction in the 
production of ATPa and GTPa
Precaution for use in the elderly; 
acute pancreatitis, acute renal 
failure, leukopenia
High level of toxicity 40-43
Sodium stibogluconate 
(Pentostam®) 
(20 mg kg-1 day-1 i.v.a 
for 10 or 20 days)
Inhibits type I DNA 
topoisomerase
Low concentrations induce 
increases in ROSa formation, 
alter the state of phagocyte 
activation; affects the production 
of superoxide, indicating that 
the activity of NADPH oxidase 
is enhanced
May cause diabetes mellitus, 
proteinuria, hypotension, 
myalgia, headache
42, 44-46
Amphotericin B/liposomal 
amphotericin B 
(10 mg kg-1 day-1)
Macrocyclic, polyene antifungal 
agent, it is thought to act by 
binding to ergosterol, the 
principal sterol in fungal cell 
membranes and Leishmania 
cells
Change in membrane 
permeability, causing metabolic 
disturbance, leakage of 
small molecules and, as a 
consequence, cell death
Hyperpyrexia, severe malaise, 
hypotension, thrombophlebitis, 
azotemia, renal tubular damage, 
hypokalemia, anemia and 
hepatitis
47, 48
Miltefosine 
(One 50 mg capsule twice 
daily with food 
(breakfast and dinner)) 
Involves interaction with lipids 
(phospholipids and sterols), 
including membrane lipids, 
inhibition of cytochrome 
C oxidase (mitochondrial 
function), and apoptosis
Protein kinase B (Akt) inhibitor, 
a serine/threonine-specific 
protein kinase that plays an 
important role in several cellular 
mechanisms, such as glucose 
metabolism, cell proliferation 
and migration, regulating 
cellular survival
Low therapeutic effect 
suggested resistance, high 
cost, teratogenic and severe 
gastrointestinal side effects, 
such as vomiting and nausea
49, 50
aTDR1: thiol dependent reductase; ATP: adenosine triphosphate; GTP: guanosine triphosphate; i.v.: intravenously; ROS: reactive oxygen species.
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of action of antimonials is based on the interference of 
amastigote bioenergetic process. Metabolic compounds 
of the drug inhibit different parasite proteins, particularly 
enzymes involved in glycolysis and fatty acid oxidation, 
resulting in a reduction in the production of adenosine 
triphosphate (ATP) and guanosine triphosphate (GTP),42 
and reports have raised the possibility that antimony 
could trigger apoptosis.47 In addition to antimonials, other 
drugs have been used as alternatives in the treatment 
of leishmaniasis, among which amphotericin B and 
pentamidine stand out. 
Pentamidine (Figure 1) is an aromatic diamine, which 
can be used in the treatment of visceral and mucocutaneous 
leishmaniasis resistant to antimonials or in individuals 
intolerant to antimony treatment. It is a molecule of great 
interest in the treatment of antimony refractory visceral 
and mucocutaneous leishmaniasis.61-63 In Brazil it has been 
used mainly to treat infections caused by L. (V.) guyanensis, 
which generally respond poorly to antimony treatment. The 
use of pentamidine in both VL and ATL treatment is limited 
by toxicity. The side effects are severe and prolonged, such 
as hypoglycemia, arrhythmia, renal failure, pancreatitis, 
and diabetes mellitus.64 Its mechanism of action is not 
well defined. It is possible that pentamidine inhibits 
synthesis of polyamines, putrescine and spermidine.65-68 
This drug may also act binding to kinetoplast DNA.69,70 
Studies have shown that the mitochondria is an important 
target of the drug, which may act inhibiting mitochondrial 
type I DNA topoisomerase,71-73 as well as affecting 
membrane potential.74,75
Amphotericin B (Figure 1) is a macrolide antibiotic 
derived from a strain of Streptomyces nodosus, belongs to 
the group of second generation leishmanicidal drugs and 
is extensively used in case of failures in the treatment with 
antimony compounds.76 Despite its high toxicity and the 
requirement of parenteral administration, amphotericin B 
has been proposed as a therapeutic agent of choice for 
MCL and VL.50,77,78 In the last decades, several new lipid 
formulations of amphotericin B have been developed to 
reduce toxicity. These formulations include liposomal 
amphotericin B (Ambisome), amphotericin B colloidal 
dispersion (Amphocil) and amphotericin B lipid complex 
(abelcet).79-81
Its mechanism of action is related to its binding to the 
fungal membrane steroid, acting on the cell membrane 
ergosterol. As the membrane of Leishmania also contains 
ergosterol, a lipid not present in the human host, the 
drug alters their permeability, with loss of small cations, 
Figure 1. Chemical structures of glucantime (meglumine antimoniate) (1), meglumin (2), sodium stibogluconate (commercialized as Pentostam) (3), 
amphotericin B (4), pentamidine (5) and miltefosine (6).
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particularly K+, causing cell death.82 But their use is limited 
by adverse effects, such as anaphylaxis, thrombocytopenia, 
generalized pain, convulsions, fever, phlebitis, anemia, 
anorexia, and decreased renal tubular function.83
Miltefosine (Figure 1), an alkylphosphocholine 
(commercial names Impavido and Miltex), was approved 
for the treatment of human VL infections in 1996.84 
Described in the 1980s as an anti cancer agent, it was later 
found to have antileishmanial activity and introduced for 
treatment of VL in the late 2002 as the first oral drug for 
treatment of human leishmaniasis.15,85 Miltefosine is a 
protein kinase B (Akt) inhibitor, a serine/threonine-specific 
protein kinase that plays an important role in several 
cellular mechanisms, such as glucose metabolism, cell 
proliferation and migration, regulating cellular survival.49 
However, the long half-life (100 to 200 h) of miltefosine in 
humans and low therapeutic effect suggested that resistance 
could rapidly develop. Furthermore, miltefosine high cost, 
teratogenic and severe gastrointestinal side effects, such 
as vomiting and nausea, observed in 60% of the patients 
treated, reduce its efficacy.49,50 Currently, among the drugs 
used in the treatment of VL infections, the first line of drugs 
are still pentavalent antimonials. 
1.2. New tested drugs and promising targets for VL and ATL
In recent years, clinical trials of novel drugs and 
therapies for VL and ATL are being developed. Over the 
past decade, the focus has been the search for a more 
effective topical formulation for the treatment of CL and 
oral formulations to treat VL. Paramomycin (Figure 2) is 
an aminoglycosidic antibiotic that belongs to the neomycin 
family. There is evidence that the antimycotic azoles, 
ketoconazole, itraconazole and fluconazole (Figure 2) 
show activity against Leishmania. Clinical trials employing 
azoles against CL, MCL and VL have been carried out 
and their effectiveness were shown to be varied.86-89 An 
immunomodulatory drug, imiquimod (Figure 2) is currently 
being administered with antimony in CL treatment to 
increase leishmanicidal activity.90-94
The rational chemotherapeutic approaches are 
focused on the metabolic differences between parasite 
and mammals. Some Leishmania enzymes are accepted 
as valid drug targets; among them are those involved 
with the parasite glycolytic pathway, the metabolism by 
trypanothione reductase, some cysteine proteases and 
dihydrofolate reductase.95-99 
Figure 2. Chemical structures of paromomycin (1), ketoconazole (2), itraconazole (3), fluconazole (4) and imiquimod (5).
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The biosynthesis of polyamines is a metabolic 
pathway that has been successfully exploited for the 
development of antiparasitic drugs.100 The first enzyme 
in the pathway, ornithine decarboxylase (ODC) catalyzes 
the conversion of ornithine to putrescine. As it is a key 
enzyme in the pathway, its inhibition may provide a tool 
for anti-parasitic therapy.101,102 Leishmania and other 
trypanosomatides require the reduction of folates and 
pterines for proliferation, suggesting that the inhibition 
of these pathways may be an effective target for 
chemotherapy. The enzymes involved in the use of folate, 
such as dihydrofolate reductase (DHFR) and thymidylate 
synthase (TS), are important targets.103,104 A promising 
molecular target is trypanothione reductase, which is 
involved in the defense against oxidative damage in the 
parasite. The system of trypanothione in trypanosomatids 
is the only thiol redox system which protects the parasite, 
representing a promising source of metabolites and 
enzymes that have potential as molecular targets for anti-
parasitic drugs.105,106 Finally, the structural differences 
between human and parasite topoisomerase enzymes set 
these molecular targets of interest for chemotherapeutic 
intervention, particularly topoisomerase II. This enzyme 
is required for kinetoplast replication and studies have 
shown that topoisomerase inhibitors have in vitro activity 
against Leishmania parasites.107,108
2. Chagas Disease Biological Aspects
Chagas disease, also known as American trypanosomiasis 
or New World trypanosomiasis, is caused by the flagellate 
protozoan Trypanosoma cruzi. T. cruzi gains access to 
the human bloodstream through injured skin or mucous 
membranes with infected feces of triatomine bugs 
(Hemiptera: Reduviidae), also known as kissing bugs. 
Other forms of infection have been reported and are of 
epidemiological relevance, such as blood transfusion, 
congenital infection, organ donation or contaminated 
food.109-112 The disease was discovered by the Brazilian 
physician Carlos Chagas in 1909 when working in 
Lassance, in the state of Minas Gerais, to control the malaria 
outbreak that was hampering the construction of the Rio 
de Janeiro to central and northern Brazil railroad. Despite 
this seminal work113 and a continuous investigation of the 
parasite life cycle and physiology, only two compounds are 
in use for Chagas disease patient treatment. 
The parasite has a complex life cycle that involves the 
invertebrate host, the triatomine bug, and the mammalian 
host, passing through several developmental stages as the 
T. cruzi cell migrates in the insect vector and the mammalian 
blood stream and intracellular digestive vacuole.
Chagas disease infections in humans are characterized 
by three distinct and well-documented clinical phases. In 
the acute phase114,115 that lasts 4 to 8 weeks, most patients 
have mild, self-limited symptoms such as fever and edema 
at the infection point (chagoma), depending on the parasite 
load. At this stage T. cruzi cells can be easily detected in 
the bloodstream and parasitemia gradually decreases as the 
infection progresses. The fatality rate at this stage, due to 
complications of the clinical condition, is estimated to be in 
the range of 0.25 to 0.50%.115 The acute phase is succeeded 
by an indeterminate phase, generally asymptomatic and 
comprising a period of 10 to 20 years.115,116 Approximately 
30% of the infected patients develop the chronic form of 
the disease, which may result into three different clinical 
manifestations: the cardiac, gastrointestinal forms or both 
simultaneously, the cardiodigestive form of Chagas disease. 
Of the patients that enter the chronic form, 60% die within 
7 months to 2 years of the initial symptoms.
Due to its clinical cycle, the socioeconomic 
characteristics of the affected population, presence of 
infected insect vectors and absence of an appropriate 
chemotherapy protocol, Chagas disease is considered 
a major public health problem in many countries. It 
affects about 7-8 million people in a vast and populated 
region of the American continent that comprises the 
southern United States down to Patagonia, representing 
an endemic area of 21 countries, claiming approximately 
14,000 deaths per year with another 100 million people 
at risk of contamination.117,118 Beyond the human live 
toll, it is estimated that a social and economic cost of 
700,000 disability-adjusted life years (DALYs) per year 
are attributed to T. cruzi infection.119,120 Human infection 
of T. cruzi in South America (Chile) can be traced back 
9,000 years, to the Chinchorro settlers, indicating a long 
period of adaptation to the human host, having a longer 
evolutionary history of adaptation to the mammalian 
parasitic lifestyle. This adaptation has lead to a robust 
human cycle that explains, in part, the present difficulty in 
developing a suitable chemotherapy. 
2.1. Chagas disease chemotherapy: challenges, progress 
and limitations
The long history of Chagas disease chemotherapy had 
its beginning shortly after the description of the disease 
in 1909 with the employment of arsenical compounds 
(atoxyl), rosanilin dye (fuchsin), antimonials and mercury 
chloride (Figure 3), all of them without effective results.121 
The discovery in the 1950s and 1960s of the nitrofuran-
containing drugs led to several attempts for T. cruzi infection 
treatment, with controversial results and questionable clinical 
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significance.122,123 Part of the failure in identifying a suitable 
drug was due to the lack of an appropriate methodology in 
the execution of clinical trials, preferential selection of acute 
instead of chronic cases and systematic use of symptom 
remission instead of parasitological diagnosis, to assess the 
success of the cure.124 
In subsequent works (Pan American Health Organization 
(PAHO)/WHO 1998)125 it was proposed that an ideal drug 
for the treatment of Chagas disease should fulfill several 
requirements: (i) The drug should show parasitological 
cure for both the acute and the chronic phase; (ii) it has to 
be effective in short treatment periods, preferentially in a 
single or few doses and without the need for hospitalization; 
(iii) be of low cost; (iv) result in no collateral or teratogenic 
side effects; and (v) the drug should not induce the 
selection of resistant strains of T. cruzi. This list of 
requirements has not been met by any compound tested 
so far. In the 1960s and 1970s two drugs were developed, 
that are still today the only options for Chagas disease 
treatment: nifurtimox (Lampit®, Bayer), 3-methyl-4-
(5’-nitrofurfurylideneamino)tetrahydro-4H-1,4-thiazine-
1,1-dioxide (Figure 3), and benznidazole (Rochagan®, 
Roche), N-benzyl-2-nitroimidazole acetamide (Figure 3).126 
Some characteristics of these drugs are summarized in 
Table 2. The action of these drugs is directly affected by 
certain conditions, such as the duration of treatment, age 
and geographic distribution of patients, among others. 
Moreover, in adult patients in the chronic phase of infection, 
the best results were obtained in southern Brazil, Argentina 
and Chile, probably due to the type of T. cruzi strain 
predominanting in the region.121
These compounds have shown low biochemical 
specificity in its action mode, contributing to the cytotoxic 
effects observed during treatment. The most common 
effects observed for nifurtimox are anorexia, weight loss, 
drowsiness, nausea, vomiting and intestinal cramps.127 
The most common side effects of benznidazole can be 
separated into three classes: (i) hypersensitivity, such as 
dermatitis, with a rash that appears usually between the 
7th and 10th days of treatment, periorbital or generalized 
edema, fever, lymphadenopathy, muscle and joint pain; 
(ii) bone marrow depression that includes neutropenia, 
agranulocytosis and thrombocytopenia; and (iii) peripheral 
neuropathy, represented by paresthesia and polyneuritis.127
Drug discovery and development encompass a diverse 
number of strategies and a combination of traditional and 
modern methods that integrate specialties, such as biology 
and biochemistry, medicine and epidemiology, chemistry 
and pharmacology, among several others. The crucial 
step is, without doubt, the identification and validation of 
molecular targets in the parasite that are suitable for drug 
screening and design. The process is time-consuming and 
requires significant financial investment, usually available 
in large pharmaceutical companies. Coupled with a reduced 
financial return, it results in low commitment of the large 
pharmaceutical industries to parasitic diseases worldwide. 
This scenario renders Chagas disease the rank of an 
extremely neglected disease.136
2.2. New tested drugs for Chagas disease
Benznidazol has been a commercially available drug 
in Brazil for several years, and more recently in Argentina, 
Chile and Uruguay. After the introduction of nifurtimox 
and benznidazol (Figure 3), few compounds were assayed 
in chagasic patients.
Allopurinol (Zyloprim), 4-hydroxypyrazolo-(3,4-d)-
pyrimidine HPP (Figure 4), is a hypoxanthine analog 
Figure 3. Chemical structures of atoxyl (1), fuchsin (2), nifurtimox (3) and benznidazole (4).
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and an alternative substrate to hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), of the purine salvage 
pathway, leading to the formation of non-physiological 
nucleotides and interfering with RNA and protein synthesis. 
Allopurinol has been tested with some promising results, 
but requires reevaluation of its efficacy in double blind 
randomized longitudinal studies.131-133 This drug has shown 
activity against Leishmania and, subsequently, against 
T. cruzi.137-139 In some cases it has shown low efficacy 
as a single therapy drug but in combination with other 
compounds it is a viable alternative.43,140 
T. cruzi displays similarities to fungi in its sterol 
biosynthesis pathway indicating this pathway as a potential 
drug target. Ketoconazole (cis-(dl)-1-acetyl-4-[4-[[(2-2,4-
dichlorophenyl)-2-(1H-imidazol-1-methyl)-1,3-ioxalan-4-
yl]methoxy]-phenyl] piperazine) (Figure 2) shows in vitro 
activity against T. cruzi epimastigotes, with accumulation 
of metabolites of the sterol metabolism. Ketoconazole 
tested in acute phase experimental animals resulted in 
parasitological cure but was shown to be ineffective in the 
chronic phase.127
Fluconazole (α-(2,4-difluorophenyl)- α-(1H-1,2,4,-
triazol-1-ylmethyl)-1H-1,2,4-triazol-1-ethanol, and 
itraconazole (cis-4[4-4-4[[2-(2-4-dichlorophenyl)-2-(1H-
1,2,4,triazol-1-methyl)-1,3-dioxolan-4-yl]-1-piperazinyl]
phenyl]-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazol-
3-one) (Figure 2), have been assayed in T. cruzi infected 
experimental animals, and their mechanism of action 
involves the interference on ergosterol synthesis leading 
to the development of the D(+) isomer of fluconazole that 
was shown to be promising.127,135 
Table 2. Drug discovery summary for the treatment of Chagas disease
Drug Mechanism of action Outcome Disadvantage Reference
Arsenical 
Rosanilin dye 
Antimonials 
Mercury chloride
Depends on the T. cruzi strain – No effects 121-123
Nifurtimox 
(3-Methyl-4-(5’-
nitrofurfurylideneamino)
tetrahydro-4H-1,4-thiazine-
1,1-dioxide) 
15 mg kg-1 day-1 for 120 days, 
acute phase; 10 mg kg-1 day-1 for 
30 or 120 days, chronic phase)
Induces oxidative stress in the 
parasite, activates reduction by a 
eukaryotic type I nitroreductase, 
inhibits parasite dehydrogenase 
activity and affects mitochondrial 
membrane potential
Anorexia, weight loss, 
drowsiness, nausea, vomiting  
and intestinal cramps
Toxic side effects 124, 127, 
128
Benznidazole 
N-Benzyl-2-nitroimidazole 
acetamide 
(5-10 mg kg-1 day-1 for 30 or 
60 days)
Induces the formation of free 
radicals and electrophilic 
metabolites within the parasite; 
induces lesions in  
the mitochondrial DNA
Hypersensitivity, dermatitis, 
generalized edema, 
fever, lymphadenopathy, 
muscle and joint pain, 
neutropenia, agranulocytosis, 
thrombocytopenia, peripheral 
neuropathy
Effective at parasite eradication 
in the acute phase of infection 
but not in the prevalent chronic 
stage of the disease
127, 129, 
130
Allopurinol 
(4-Hydroxypyrazolo-
(3,4-d)-pyrimidine HPP) 
(8-10 mg kg-1 for 60 days)
Alternative substrate to HGPRT,a 
of the purine salvage pathway, 
leading to the formation of non-
physiological nucleotides and 
interfering with RNA synthesis
Headache, nausea, weight loss, 
dark urine, jaundice, muscle 
weakness, vomiting, diarrhea
Ineffective during the  
acute phase
131-134
Fluconazole 
((α-(2,4-difluorophenyl)-α-
(1H-1,2,4,-triazol-1-ylmethyl)-
1H-1,2,4-triazol-1-ethanol) 
(5-6 mg kg-1 day-1 for 60 days)
Inhibits the cytochrome P450 
enzyme, important for ergosterol 
in the cytoplasmic membrane, 
increased permeability
No significant side effects – 127, 134, 
135
aHGPRT: hypoxanthine-guanine phosphoribosyltransferase. 
Figure 4. Chemical structures of allopurinol (1) and miconazole (2).
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2.3. Trypanosoma cruzi promising targets
Developments in T. cruzi  biochemistry and 
genomics allowed the identification of potentially novel 
chemotherapy targets.141-143 The increasing understanding 
of kinetoplastid biochemical pathways has allowed 
the development of new drugs and the identification 
of potential new targets. Among the various metabolic 
pathways that are being currently studied,144,145 some of 
relevance are the purine salvage pathway, polyamine and 
thiol metabolism, folate biosynthesis, DNA replication, 
glycolytic pathway and fatty acid biosynthetic pathways 
and sterol biosynthesis.
Sterol biosynthesis
Sterols are essential components of cell membranes. 
It has been shown that trypanosomatids incorporate 
cholesterol from complex culture medium containing either 
brain, heart or liver extracts and bovine serum or from the 
blood of infected animals. Ergosterol is the main sterol of 
T. cruzi produced by the sterol biosynthesis pathway, which 
thus makes this pathway such an attractive target for drug 
development.146
Among representative inhibitors of ergosterol 
biosynthesis are the triazole posaconazole that inhibited 
epimastigote proliferation more efficiently than 
ketoconazole and the D(+) isomer of fluconazole.147 
However, generation of resistant T. cruzi cells to azoles, 
such as fluconazole, ketoconazole, itraconazole (Figure 2) 
and miconazole (Figure 4), points to difficulties in the use 
of such compounds as chemotherapeutic agents.148 
Purine salvage pathway 
Purine salvage pathway in trypanosomatids is 
attractive since these organisms are unable to synthesize 
purines de novo. Purine nucleotides are important as 
precursors of nucleic acids, and function as second 
messengers and modulators of enzyme activities. Therefore, 
trypanosomatids either are dependent of the host supply 
of purines or have to salvage purines.149 Enzymes from 
the purine salvage pathway have been detected in T. cruzi 
and Leishmania species, including adenine phosphoribosyl 
transferase (APRT), hypoxanthine-guanine-xanthine 
phosphoribosyl transferase (HGXPRT), adenosine kinase 
(AK) and nucleoside hydrolase (NH).150,151
Several inhibitors of the salvage pathway enzymes 
were evaluated for antiparasitic activity, however, some 
authors considered parasitic growth inhibition induced 
by these inhibitors to be disappointing151 because the 
parasites can circumvent this inhibition through alternative 
metabolic pathways. In this way, some research groups 
have investigated subversive substrates as potential drugs.152 
Although not directly intervening in the purine salvage 
pathway, the subversive substrates are metabolized by 
salvage enzymes being activated by a toxic product, e.g., 
allopurinol (Figure 4).139,151,153
Thiol and polyamine metabolism
Enzymes involved in trypanothione metabolism are 
found exclusively in Kinetoplastida protozoa and do not 
have an equivalent in the mammalian host. They participate 
in protection of the organism against oxidative stress 
and redox homeostasis. In this pathway, trypanothione 
reductase, that catalyzes the reduction of trypanothione 
from its disulfide oxidized form, has been investigated as a 
target enzyme for generation of potential inhibitors against 
leishmaniasis and Chagas disease.152,154,155
The enzymes ornithine decarboxylase (ODC) or 
S-adenosylmethionine decarboxylase (AdoMetDC), 
involved in spermidine synthesis, have become attractive 
targets for the development of new chemotherapies against 
trypanosomiasis and leishmaniasis as well.156
Glycolytic pathway
The bloodstream form of T. cruzi relies on glycolysis for 
its ATP. The enzymes for the glycolytic pathway are, in its 
majority, compartmentalized in specialized organelles, the 
glycosomes.157 Due to the evolutionary distance between 
T. cruzi and humans, the parasite glycolytic enzymes have 
distinct properties from their mammalian homologues that 
can be exploited in the design of parasite-specific drugs. 
Inhibitors to phosphofructokinase (PFK) and pyruvate 
kinase (PyK) have shown potential as antitrypanosomal 
and antileishmanial drugs.158 Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) inhibitors have been studied but 
in vivo effects have not been observed.159,160 Several classes 
of selective inhibitors have been designed as potential 
trypanocidal compounds.161,162 One class comprises 
substrate analogues.163 A second class mimics the transition 
state and high-energy intermediates of the enzymatic 
reaction.164,165
A fascinating feature of these parasites that gives 
them the order name of Kinetoplastidae, is the presence 
of a concatenated mitochondrial DNA comprised of 
thousands of smaller DNA plasmid-like molecules called 
the minicircles and larger DNA circles, similar to the 
conventional mitochondrial DNA, called the maxicircles.166 
This network of concatenated circles of DNA is replicated 
at each division cycle of the parasite, and requires the 
action of enzymes DNA topoisomerase I (EC 5.99.1.2) 
and II (EC 5.99.1.3). These enzymes have attracted 
great attention to the development of kinetoplast DNA 
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replication inhibitors as chemotherapeutic agents.167 Several 
commercially available drugs have shown a varied degree of 
inhibition to kinetoplastid topoisomerases. Anthracyclines, 
camptothecins, acridines and fluoroquinolones are well-
known inhibitors, which showed promising results against 
blood trypomastigotes of T. cruzi.168
3. Conclusions
At present, chemotherapy is the only viable route 
for treatment of protozoa infectious disease caused by 
kinetoplastid parasites (Leishmania, Trypanosoma), 
although exciting advances have been made toward 
the development of vaccines. However, the available 
therapies are far from satisfactory. Recent advances on 
genomics, with the mapping of several protozoa parasite 
genomes, transcriptomes and proteomes, together with a 
significant advance in standardization of target validation 
methods, lead compound testing protocols and awareness 
of parasite diversity are leading to a more complete 
definition of strategies for drug discovery. Advances in 
the area of parasite protein structural biology and the 
biochemical assessment of enzyme kinetic parameters, 
in silico techniques for compound docking and screening 
have created new tools that may lead to a future drug 
discovery. The in silico drug design approaches provide 
pivotal information to synthesize compounds that exhibit 
selectivity for specific targets. The interaction between 
compound and protein can be optimized by computer-based 
molecular docking. These approaches select compounds 
that are able to eliminate the parasite, but do not consider 
parasite in the host context. Thus, methodologies of 
phenotypic analysis, like high-content screening (HCS), 
should be used to integrate information about the parasite, 
the target and the host cells. It is important to combine 
several approaches to overcome some of the challenges of 
anti-trypanosomatids drug discovery.
In an effort to integrate information and create new 
opportunities for drug discovery and development, a special 
program within the WHO, the Tropical Disease Research 
(TDR), has developed a database (TDR targets database, 
https://www.tdrtargets.org). This database aims to facilitate 
the identification and prioritization of drugs and drug targets 
in neglected disease pathogens. 
Nevertheless, all these advances are dependent on 
a coordinated effort between different laboratories in 
academic institutions, pharmaceutical industry and 
governmental agencies with a clear agenda of objectives, 
management of results, definition of protocols and 
interpretation of results to treat the “neglected” diseases 
of the “neglected” populations.
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